A Phase 1 Study of LY2801653 in Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 25 Mar 2017
At a glance
- Drugs Merestinib (Primary) ; Cetuximab; Cisplatin
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Head and neck cancer; Solid tumours; Squamous cell cancer; Uveal melanoma
- Focus Adverse reactions
- Sponsors Eli Lilly
- 20 Jan 2017 Planned End Date changed from 1 Nov 2017 to 17 May 2018.
- 20 Jan 2017 Planned primary completion date changed from 1 Nov 2017 to 17 May 2018.
- 08 Sep 2015 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017 as reported by ClinicalTrials.gov